Current Research Studies

APEC1621SC: Pediatric MATCH (Molecular Analysis for Therapy Choice)

APEC1621SC

  • Condition(s): Adrenal Tumors, Adrenocortical Carcinoma, Anaplastic Large Cell Lymphoma (ALCL), Atypical Teratoid/Rhabdoid Tumor, Brain Tumor, Burkitt's Lymphoma, CNS Embryonal Tumors, CNS Germ Cell Tumors, CNS Sarcoma, Choroid Plexus Tumors, Clear Cell Sarcoma of the Kidney, Craniopharyngioma, Diffuse Intrinsic Pontine Glioma (DIPG), Diffuse Large B-cell Lymphoma (DLBCL), Diffuse Midline Glioma (DMG), Ependymoma, Ewing Sarcoma, Germ Cell Tumors, Glioneuronal and Neuronal Tumors, Hepatoblastoma, Hepatocellular Carcinoma, High-Grade Glioma, Histiocytic Tumors, Juvenile Xanthogranuloma (JXG), Langerhans Cell Histiocytosis (LCH), Leukemia & Lymphoma, Liver Tumors, Low-Grade Glioma, Lymphoblastic Lymphoma (LBL), Malignant Bone Tumors, Medulloblastoma, Neuroblastoma, Non-Hodgkin Lymphoma (NHL), Non-rhabdomyosarcoma Soft Tissue Sarcomas, Osteosarcoma, Other, Pheochromocytoma, Pilocytic Astrocytoma, Recurrent and/or Refractory, Registry, Renal Cell Carcinoma, Renal Tumors, Retinoblastoma, Rhabdoid Tumor of the Kidney, Rhabdomyosarcoma, Soft Tissue Sarcomas, Solid Tumor, Thyroid Cancer, Wilms Tumor
  • Phase: N/A
  • Clinicaltrials.gov ID: NCT03155620

What is the goal of the study?

The goal of this phase 2 study is to evaluate patients' overall response rate to treatment.

Who can participate in the study?

This study may be a good fit for children and young adults who: - are between the ages of 12 months to 21 years old, and - have a diagnosis of recurrent or refractory solid tumors, including non-Hodgkin lymphomas; histiocytoses (e.g. langerhans cell histiocytosis [LCH], juvenile xanthogranuloma [JXG], histiocytic sarcoma); or central nervous system (CNS) tumors.

Study Team: